Palonosetron oral - Roche/Helsinn
Alternative Names: Aloxi CapsuleLatest Information Update: 25 Jan 2023
Price :
$50 *
At a glance
- Originator Roche
- Developer Chugai Pharma Europe; Helsinn; Sinclair IS Pharma
- Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 24 Jan 2023 Immedica in-licenses palonosetron from Helsinn for commercialization in Switzerland, Belgium and Liechtenstein
- 27 Dec 2022 No development reported - Clinical-Phase-Unknown for Chemotherapy-induced nausea and vomiting (Prevention) in China (PO) (Helsinn Healthcare pipeline, December 2022)
- 17 Mar 2020 Helsinn announces intention to submit MAA to National Medical Products Administration for Chemotherapy-induced nausea and vomiting (Prevention) in China (Helsinn Healthcare pipeline, March 2020)